Filter Results:
(621)
Show Results For
- All HBS Web
(621)
- People (2)
- News (57)
- Research (447)
- Events (2)
- Multimedia (9)
- Faculty Publications (391)
Show Results For
- All HBS Web
(621)
- People (2)
- News (57)
- Research (447)
- Events (2)
- Multimedia (9)
- Faculty Publications (391)
- 29 Jun 2022
- Blog Post
Harvard Business School Announces the 2022-2023 Blavatnik Fellows
led by Peter Barrett, PhD, faculty chair, and an advisory board of seasoned business and biotechnology leaders who serve as one-on-one mentors and provide strategic direction during the fellows' program year. “Since joining the Blavatnik... View Details
- 16 Jun 2003
- Research & Ideas
Surveying the VC Landscape
public within five to seven years of its initial financing, will be able to pursue research that will not have a payoff for fifteen, twenty, or even more years in the future. (But it's not impossible—after all, venture capital has played a key role in the financing of... View Details
- 12 Mar 2013
- First Look
First Look: March 12
A. Arnaout Publication:Nature Biotechnology Abstract Advances in biotechnology have fueled the generation of unprecedented quantities of data across the life sciences. However, finding analysts who can... View Details
Keywords: Sean Silverthorne
- 11 Jun 2020
- In Practice
Are Digital Organizations Better at Overcoming COVID?
chains and people analytics to artificial intelligence-based models and automated biotechnology research, organizations further along the digital curve are responding differently than those still wondering how to evolve. The digital... View Details
Keywords: by Danielle Kost
- 01 Mar 2005
- News
A Primer on Patents
fifteen years ago, as a doctoral candidate in Harvard’s Economics Department, Lerner was collecting data on the role of VC funding in the biotechnology industry. Before long, he also became intrigued by the concept of intellectual... View Details
- 01 Mar 2003
- News
Naina Lal Kidwai
to the global automobile industry. Biotechnology and pharmaceutical firms are emerging as international players. There are also opportunities in infrastructure investment, such as telecom, ports, roads, and airports. Please comment on... View Details
- September 2024
- Case
Myeloma Investment Fund
By: Kyle Myers and Scott Sawaya
This case explores a critical decision facing the Myeloma Investment Fund (MIF) as it evaluates two investment opportunities aimed at accelerating a cure for multiple myeloma.
The MIF, a venture philanthropy fund, must choose between two distinct paths. One... View Details
The MIF, a venture philanthropy fund, must choose between two distinct paths. One... View Details
Keywords: Venture Philanthropy; Biomedical Research; Investing For Impact; Innovation & Entrepreneurship; Venture Capital; Science-Based Business; Philanthropy and Charitable Giving; Decision Making; Health Care and Treatment; Biotechnology Industry; Biotechnology Industry
Myers, Kyle, and Scott Sawaya. "Myeloma Investment Fund." Harvard Business School Case 625-047, September 2024.
- November 2014
- Teaching Note
Claritas Genomics
By: Robert F. Higgins and Matthew G. Preble
Dr. Patrice Milos is the first CEO of Claritas Genomics (Claritas) and she faces a number of challenges in scaling the young company. Claritas was formed around a lab spun out from Boston Children's Hospital (BCH) which had performed genomic tests for the hospital. Now... View Details
- September 2014
- Case
Pfizer's Centers for Therapeutic Innovation (CTI)
By: Gary Pisano, James Weber and Kait Szydlowski
In 2010, Pfizer established four small research units in New York, Boston, San Francisco, and San Diego located close to several premier Academic Medical Centers (AMCs), or hospitals with adjoining medical schools. The goal of these units was to redesign collaboration... View Details
Keywords: Drug Development; Academic Collaboration; Research And Development; Innovation; Translational Research; Management; Operations; Problems and Challenges; Research; Science; Information Technology; Strategy; Biotechnology Industry; Biotechnology Industry; North and Central America; Europe; Asia
Pisano, Gary, James Weber, and Kait Szydlowski. "Pfizer's Centers for Therapeutic Innovation (CTI)." Harvard Business School Case 615-024, September 2014.
- June 2013
- Supplement
Can PACIV (Puerto Rico) Serve European Customers? (Video Supplement)
By: Jim Sharpe
This is Video Supplement for Can PACIV (Puerto Rico) Serve European Customers? HBS Case #808099. View Details
Keywords: Entrepreneurial Management; Global Organizations; Service; Hiring; Incentives, Motivation; Joint Ventures; Customer Service Excellence; Customer Relationship Management; Empowerment; International Expansion; Ownership Structure; Culture; Organization Alignment; Growth and Development Strategy; Entrepreneurship; Private Ownership; Globalized Markets and Industries; Globalized Firms and Management; Biotechnology Industry; Biotechnology Industry; Puerto Rico; United Kingdom
Sharpe, Jim. "Can PACIV (Puerto Rico) Serve European Customers? (Video Supplement)." Harvard Business School Video Supplement 813-722, June 2013.
- December 2010
- Teaching Note
Roche's Acquisition of Genentech (TN)
By: Bo Becker and Carliss Y. Baldwin
Teaching Note for 210-040. View Details
- 11 Oct 2009
- Conference Presentation
The impact of institutional actors as attention structures on entrepreneurial activity in the U.S. biodiesel industry
By: Shon R. Hiatt
- November 2009
- Case
The Explosion of Genetic Testing: Opportunities and Challenges
By: Richard G. Hamermesh, Mara G. Aspinall and Rachel Gordon
This case study invites the reader to consider genetic testing in several different lights. First, can the business of genetic testing be considered a disruptive innovation to the current drug therapy model as defined by Harvard Business School Professor Clay... View Details
- October 2009 (Revised July 2013)
- Case
Gilead Sciences, Inc.: Access Program
By: V. Kasturi Rangan and Katharine Lee
Gilead Sciences, the U.S. leader in HIV/AIDS medicines, with global sales of $5.4 billion in 2009, had undertaken several innovative actions to make its anti-viral products available to over 100 low- and middle-income countries. Having reached nearly 680,000 patients... View Details
Keywords: Health Care and Treatment; Emerging Markets; Product; Sales; Competitive Strategy; Biotechnology Industry; Biotechnology Industry
Rangan, V. Kasturi, and Katharine Lee. "Gilead Sciences, Inc.: Access Program." Harvard Business School Case 510-029, October 2009. (Revised July 2013.)
- June 2008
- Case
Gordon Williams: Clinical Research at Brigham and Women's Hospital
By: H. Kent Bowen and Courtney Purrington
Clinical research is a critical element of biomedical research and development. This case describes the challenges of clinical research, and its role in bringing breakthroughs to patients. Dr. Williams leads through his own research and special programs to train... View Details
Keywords: Training; Health Care and Treatment; Success; Programs; Research and Development; Biotechnology Industry; Biotechnology Industry
Bowen, H. Kent, and Courtney Purrington. "Gordon Williams: Clinical Research at Brigham and Women's Hospital." Harvard Business School Case 608-168, June 2008.
- June 2003 (Revised October 2004)
- Case
Novartis: The Challenge of Success (D)
By: Sandra J. Sucher and Stacy McManus
Supplements the (A) and (B) cases. View Details
Sucher, Sandra J., and Stacy McManus. "Novartis: The Challenge of Success (D)." Harvard Business School Case 603-046, June 2003. (Revised October 2004.)
- 22 Nov 2016
- First Look
November 22, 2016
commercial implications—the technology would be immensely important to biotechnology firms looking to develop gene therapy products and was, therefore, sure to generate strong revenues for whichever entity owned the IP—but would also... View Details
Keywords: Sean Silverthorne
- Profile
Terrance McGuire
and entrepreneur, during which time they have collaborated on a long list of successful biotechnology startups. “Bob Langer is passionate about improving peoples' lives,” McGuire said. “He was one of the early... View Details
- November 2023 (Revised April 2024)
- Case
BiomX: Bringing Phage Back to the Stage
By: Paul A. Gompers, Elie Ofek, Orna Dan and Emilie Billaud
In the spring of 2023, and following the favorable results of a trial involving its phage cocktail for treating lung infections among cystic fibrosis (CF) patients, the leadership of BiomX had several critical issues to wrestle with. First, given its precarious... View Details
Keywords: Working Capital; Financing and Loans; Health Testing and Trials; Product Development; Research and Development; Science-Based Business; Commercialization; Biotechnology Industry; Biotechnology Industry
Gompers, Paul A., Elie Ofek, Orna Dan, and Emilie Billaud. "BiomX: Bringing Phage Back to the Stage." Harvard Business School Case 524-051, November 2023. (Revised April 2024.)
- September 2023 (Revised April 2024)
- Case
Atomwise: Strategic Opportunities in AI for Pharma
By: Satish Tadikonda
Abraham Heifets and his co-founder, Izhar Wallach, had founded Atomwise to develop i) an AI engine to transform drug discovery by creating better medicines faster, and ii) a machine learning-based discovery engine that combined the power of convolutional neural... View Details
Keywords: Business Model; Business Startups; AI and Machine Learning; Science-Based Business; Technological Innovation; Biotechnology Industry; Biotechnology Industry
Tadikonda, Satish. "Atomwise: Strategic Opportunities in AI for Pharma." Harvard Business School Case 824-043, September 2023. (Revised April 2024.)